Affiliation:
1. Department of Veterinary Medicine and Animal Productions General Pathology and Pathologic Anatomy Section ‐ University of Naples Federico II Naples Italy
2. Institute of Biochemistry and Cell Biology (IBBC), National Research Council (CNR) Naples Italy
Abstract
AbstractFeline oral squamous cell carcinoma (FOSCC) is characterised by invasive and metastatic behaviour and is poorly responsive to current treatments, hence the need for new therapeutic strategies. FOSCC shares molecular targets with human head and neck squamous cell carcinoma (HNSCC), among these the epidermal growth factor receptor. Cetuximab is an anti‐epidermal growth factor receptor monoclonal antibody employed in the therapy of HNSCC and, interestingly, previous work in vitro suggested that it displays cytostatic and cytotoxic properties also against FOSCC. With the present study, we aimed at further investigating the effects of cetuximab on invasion and metastasis pathways proven to be relevant in human patients. To this purpose, FOSCC cell lines SCCF1, SCCF2 and SCCF3 were treated with cetuximab for 48/72 h and subjected to Western blot for matrix metalloproteinases‐2/9 (MMP‐2/9) and epithelial–mesenchymal transition markers vimentin, E‐, P‐ and N‐cadherin. Treatment with cetuximab resulted in downregulation of MMP‐2/‐9 in all of the three cell lines in a dose‐dependent manner. Moreover, cetuximab downregulated vimentin and P‐cadherin in SCCF1, upregulated E‐cadherin whilst downregulating P‐/N‐cadherins in SCCF2, and impaired P‐/N‐cadherins in SCCF3. An in vitro scratch test also demonstrated that cetuximab delayed cell migration in SCCF3. These data suggest that cetuximab mitigates invasion and metastasis processes by impairing MMPs and epithelial–mesenchymal transition pathways in FOSCC, indicating that this monoclonal antibody may help to counteract malignant progression and improve the management of locally invasive disease.